Haematological malignancies were previously thought to be driven solely by genetic or
epigenetic lesions within haematopoietic cells. However, the niches that maintain and …

Decades of research have disclosed a plethora of alterations in protein glycosylation that
decisively impact in all stages of disease and ultimately contribute to more aggressive cell …

Abstract Uproleselan (GMI-1271) is a novel E-selectin antagonist that disrupts cell survival
pathways, enhances chemotherapy response, improves survival in mouse xenograft and …

Cell surface glycosylation is dynamic and often changes in response to cellular
differentiation under physiological or pathophysiological conditions. Altered glycosylation on …

Cell surface carbohydrates (known as glycans) are often aberrantly expressed or found at
atypical levels in cancer. Glycans can impact all steps in tumour progression, from malignant …

Abnormal glycosylation is a hallmark of cancer, and the hypersialylated tumor cell surface
facilitates abnormal cell trafficking and drug resistance in several malignancies, including …

Simple Summary This review focuses on eradicating cancer by targeting a surface protein
expressed on the endothelium—E-selectin—with a novel drug, uproleselan (GMI-1271) …

Selectins are a group of Ca2+-dependent, transmembrane type I glycoproteins which attract
cell adhesion and migration. E-selectin is exclusively expressed in endothelial cells, and its …

The bone marrow microenvironment (BMM) is the 'domicile'of hematopoietic stem cells, as
well as of malignant processes that can develop there. Multiple and complex interactions …

Remodeling of the microenvironment by tumor cells can activate pathways that favor cancer
growth. Molecular delineation and targeting of such malignant-cell nonautonomous …